{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:22:03Z","timestamp":1792297323672,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Janus kinase inhibitor ruxolitinib is approved for the treatment of myelofibrosis (MF) and improved overall survival (OS) versus control therapy in the phase 3 COMFORT trials. The aim of this retrospective analysis was to examine the real-world impact of ruxolitinib on OS in patients with MF. The US Medicare Fee-for-Service claims database (parts A\/B\/D) was used to identify patients with\u2009\u2265\u20091 inpatient or\u2009\u2265\u20092 outpatient claims with an MF diagnosis (January 2010\u2013December 2017). Eligible patients with MF were\u2009\u2265\u200965\u00a0years old (intermediate-1 or higher risk based on age). Patients were divided into 3 groups based on ruxolitinib approval status at diagnosis and ruxolitinib exposure: (1) preapproval, ruxolitinib-unexposed; (2) post-approval, ruxolitinib-unexposed; and (3) post-approval, ruxolitinib-exposed. In total, 1677 patients with MF were included (preapproval [all ruxolitinib-unexposed], <jats:italic>n<\/jats:italic>\u2009=\u2009278; post-approval, <jats:italic>n<\/jats:italic>\u2009=\u20091399 [ruxolitinib-unexposed, <jats:italic>n<\/jats:italic>\u2009=\u20091127; ruxolitinib-exposed, <jats:italic>n<\/jats:italic>\u2009=\u2009272]). Overall, median age was 78\u00a0years, and 39.8% were male. Among patients with valid death dates (preapproval, <jats:italic>n<\/jats:italic>\u2009=\u2009119 [42.8%]; post-approval, ruxolitinib-unexposed, <jats:italic>n<\/jats:italic>\u2009=\u2009382 [33.9%]; post-approval ruxolitinib-exposed, <jats:italic>n<\/jats:italic>\u2009=\u200954 [19.9%]), 1-year survival rates were 55.6%, 72.5%, and 82.3%, and median OS was 13.2\u00a0months, 44.4\u00a0months, and not reached, respectively. Risk of mortality was significantly lower post- versus preapproval regardless of exposure to ruxolitinib (ruxolitinib-unexposed: adjusted hazard ratio [HR], 0.67; ruxolitinib-exposed: adjusted HR, 0.36; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 for both); post-approval, mortality risk was significantly lower in ruxolitinib-exposed versus ruxolitinib-unexposed patients (adjusted HR, 0.61; <jats:italic>P<\/jats:italic>\u2009=\u20090.002). Findings from this study complement clinical data of ruxolitinib in MF by demonstrating a survival benefit in a real-world setting.<\/jats:p>","DOI":"10.1007\/s00277-021-04682-x","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T05:44:10Z","timestamp":1633844650000},"page":"131-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8569","authenticated-orcid":false,"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreekant","family":"Parasuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambhavi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"issue":"2","key":"4682_CR1","first-page":"121","volume":"16","author":"JM O\u2019Sullivan","year":"2018","unstructured":"O\u2019Sullivan JM, Harrison CN (2018) Myelofibrosis: clinicopathologic features, prognosis, and management. Clin Adv Hematol Oncol 16(2):121\u2013131","journal-title":"Clin Adv Hematol Oncol"},{"issue":"12","key":"4682_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ajh.25230","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A (2018) Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 93(12):1551\u20131560","journal-title":"Am J Hematol"},{"issue":"33","key":"4682_CR3","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PAW, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hern\u00e1ndez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098\u20134103. https:\/\/doi.org\/10.1200\/JCO.2012.42.3863","journal-title":"J Clin Oncol"},{"issue":"24","key":"4682_CR4","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Bj\u00f6rkholm M (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 30(24):2995\u20133001. https:\/\/doi.org\/10.1200\/JCO.2012.42.1925","journal-title":"J Clin Oncol"},{"key":"4682_CR5","doi-asserted-by":"publisher","unstructured":"Price GL, Davis KL, Karve S, Pohl G, Walgren RA (2014) Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 9(3):e90299. https:\/\/doi.org\/10.1371\/journal.pone.0090299","DOI":"10.1371\/journal.pone.0090299"},{"key":"4682_CR6","doi-asserted-by":"publisher","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","volume":"42","author":"RM Shallis","year":"2020","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM (2020) Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map. Blood Rev 42:100706. https:\/\/doi.org\/10.1016\/j.blre.2020.100706","journal-title":"Blood Rev"},{"issue":"4","key":"4682_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A (2019) 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc 94(4):599\u2013610. https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.022","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"4682_CR8","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"key":"4682_CR9","unstructured":"JAKAFI\u00ae (ruxolitinib). 2020 Full prescribing information, Incyte Corporation, Wilmington, DE, USA"},{"issue":"1","key":"4682_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V (2017) Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 10(1):156","journal-title":"J Hematol Oncol"},{"issue":"9","key":"4682_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"issue":"9","key":"4682_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"key":"4682_CR13","doi-asserted-by":"publisher","unstructured":"Passamonti F, Gupta V, Martino B, Foltz L, Zaritskey A, Al-Ali HK, Tavares R, Maffioli M, Raanani P, Giraldo P, Griesshammer M, Guglielmelli P, Bouard C, Paley C, Tiwari R, Vannucchi AM (2021) Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a phase 3b, expanded-access study. Hematol Oncol. https:\/\/doi.org\/10.1002\/hon.2898","DOI":"10.1002\/hon.2898"},{"issue":"5","key":"4682_CR14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.16462","volume":"189","author":"HK Al-Ali","year":"2020","unstructured":"Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, Garc\u00eda-Hern\u00e1ndez C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, H\u00e4nel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM (2020) Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol 189(5):888\u2013903. https:\/\/doi.org\/10.1111\/bjh.16462","journal-title":"Br J Haematol"},{"issue":"6","key":"4682_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/ejh.13330","volume":"103","author":"F Schain","year":"2019","unstructured":"Schain F, Vago E, Song C, He J, Liwing J, Lofgren C, Bjorkholm M (2019) Survival outcomes in myelofibrosis patients treated with ruxolitinib: a population-based cohort study in Sweden and Norway. Eur J Haematol 103(6):614\u2013619","journal-title":"Eur J Haematol"},{"issue":"1","key":"4682_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4274\/tjh.2016.0005","volume":"34","author":"N Soyer","year":"2017","unstructured":"Soyer N, Haznedaroglu IC, Comert M, Cekdemir D, Yilmaz M, Unal A, Cagliyan G, Bilgir O, Ilhan O, Ozdemirkiran F, Kaya E, Sahin F, Vural F, Saydam G (2017) Multicenter retrospective analysis of Turkish patients with chronic myeloproliferative neoplasms. Turk J Haematol 34(1):27\u201333. https:\/\/doi.org\/10.4274\/tjh.2016.0005","journal-title":"Turk J Haematol"},{"issue":"suppl 1","key":"4682_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-142578","volume":"136","author":"L Masarova","year":"2020","unstructured":"Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce SA, Estrov ZE, Kantarjian HM, Verstovsek S (2020) Improved survival of patients with myelofibrosis in the last decade. Blood 136(suppl 1):50\u201351. https:\/\/doi.org\/10.1182\/blood-2020-142578","journal-title":"Blood"},{"issue":"suppl 1","key":"4682_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-134161","volume":"136","author":"JW Thomas","year":"2020","unstructured":"Thomas JW, Shah MV, Vachhani P, Jamy O, Go RS, Goyal G (2020) Risk of mortality and leukemic transformation in primary myelofibrosis before and after ruxolitinib approval. Blood 136(suppl 1):28\u201328. https:\/\/doi.org\/10.1182\/blood-2020-134161","journal-title":"Blood"},{"key":"4682_CR19","doi-asserted-by":"publisher","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kr\u00f6ger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A,\u00a0European LeukemiaNet\u00a0(2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761\u2013770. https:\/\/doi.org\/10.1200\/JCO.2010.31.8436","DOI":"10.1200\/JCO.2010.31.8436"},{"issue":"20","key":"4682_CR20","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"4682_CR21","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myeloproliferative Neoplasms, version 2.2017. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed 24 June 2020"},{"issue":"1","key":"4682_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3324\/haematol.2016.158865","volume":"102","author":"LC Michaelis","year":"2017","unstructured":"Michaelis LC (2017) Risk stratification in myelofibrosis: the quest for simplification. Haematologica 102(1):2\u20133","journal-title":"Haematologica"},{"key":"4682_CR23","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for myeloproliferative neoplasms, version 1.2020. \u00a9 National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 5, 2021."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04682-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T15:09:54Z","timestamp":1641222594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04682-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4682"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04682-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study did not require approval from an institutional review board, as all analyzed data were from secondary sources and no personally identifying information was collected or reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was not required owing to the retrospective study design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. No personally identifying information was collected or reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SV received research support from AstraZeneca, Blueprint Medicines Corp, Celgene, CTI BioPharma Corp, Genentech, Gilead, Incyte Corporation, ItalPharma, Novartis, NS Pharma, PharmaEssentia, Promedior, Protagonist Therapeutics, Roche, and Sierra Oncology; and is a paid consultant for Celgene, Incyte Corporation, Novartis, and Sierra Oncology. SP and JY are employees and shareholders of Incyte Corporation. AS, SK, and AX are employees of Avalere Health, a paid consultant of Incyte Corporation. CH served on speakers bureaus for Celgene, CTI BioPharma Corp, Gilead Sciences, Incyte Corporation, Janssen, Novartis, and Shire; has received research funding (institutional) from Celgene and Novartis; and has received honoraria from AOP Orphan Pharmaceuticals, Celgene, CTI BioPharma Corp, Gilead Sciences, Novartis, Promedior, Roche, Shire, and Sierra Oncology.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}